Reactive species
Human;Mouse;Rat
Protein name
Cyclin-dependent kinase 4 inhibitor B
Immunogen
The antiserum was produced against synthesized peptide derived from human p15 INK. AA range:89-138
Specificity
p15 Monoclonal Antibody detects endogenous levels of p15 protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Monoclonal, Mouse,IgG
Dilution rate
Western Blot: 1/500 - 1/2000
Purification process
The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.
Other name
CDKN2B; MTS2; Cyclin-dependent kinase 4 inhibitor B; Multiple tumor suppressor 2; MTS-2; p14-INK4b; p15-INK4b; p15INK4B
Background
This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008],
Function
disease:Defects in CDKN2B are involved in tumor formation.,function:Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.,polymorphism:Genetic variations in CDKN2B may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus.,similarity:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.,similarity:Contains 4 ANK repeats.,subunit:Heterodimer of CDKN2B with CDK4 or CDK6.,
